SNP

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

Retrieved on: 
木曜日, 5月 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering, Medical device

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

Retrieved on: 
木曜日, 5月 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American Thoracic Society International Conference

Retrieved on: 
月曜日, 4月 29, 2024
Efficacy, Safety, Foresight, ATS, Pulmonary hypertension, Conference, House, ALDH2, Human, SNP, SVP, Aldehyde, HDM, Lung, American Thoracic Society, Asthma, Pharmacology, Pharmaceutical industry

TAIPEI, April 29, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and present two posters at the 2024 American Thoracic Society (ATS) International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.

Key Points: 
  • TAIPEI, April 29, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and present two posters at the 2024 American Thoracic Society (ATS) International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.
  • "The WINDWARD Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of FP-045 in patients with PH-ILD.
  • We could not be more confident with the role and importance of MMP-12 in immune-fibrotic diseases, particularly in the lung.
  • The posters will become available on the Foresee website after the conference.

EQS-News: SNP acquires Trigon Consulting and strengthens premium services for customers and partners

Retrieved on: 
金曜日, 5月 3, 2024
Software, Environment, SNP, Acquisition, Data management, SAP, SAP S/4HANA

Consulting specialist for IT and business transformations, data migration and digitalization joins the SNP Group with effect from May 1, 2024

Key Points: 
  • Consulting specialist for IT and business transformations, data migration and digitalization joins the SNP Group with effect from May 1, 2024
    The move expands and strengthens the SNP go-to-market model, enabling partners and customers to use SNP software more quickly
    Heidelberg, Germany, April 18, 2024 – SNP SE is expanding its premium services for customers and partners.
  • With the acquisition of the Trigon Group, based in Pullach near Munich, SNP is strengthening its premium engagement and cooperation model.
  • Our companies complement each other perfectly, and our expertise will strengthen SNP’s consulting services and expand its capacity.
  • We are thrilled to become part of this incredible team and are looking forward to the exciting journey ahead with SNP.”

EQS-News: After Record Year 2023 SNP Starts with the Best First Quarter Ever

Retrieved on: 
金曜日, 5月 3, 2024
CFO, Software, Partnership, Environment, SNP, Tax, Acquisition, Data management, Workforce, SAP, Video game

The company has made a successful start to the year with record results in all key performance indicators.

Key Points: 
  • The company has made a successful start to the year with record results in all key performance indicators.
  • Dr. Jens Amail, CEO of SNP, comments: “After record results in 2023 with an incredibly strong Q4, we started the year with our best ever first quarter.
  • The service business contributed €37.3 million (+19% compared to Q1 2023) to Group revenue; the software business €16.8 million (+6% compared to Q1 2023).
  • Andreas Röderer, CFO of SNP, comments: “With a strong first quarter, we are building on last year’s success.

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

Retrieved on: 
火曜日, 4月 23, 2024
Psilocybin, Genetics, Psilocybe, ITS, Genomics, CTAB, AGC, Panaeolus, Partnership, Health Canada, Research, KPU, Single-nucleotide polymorphism, DNA, SNP, FRA

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC).

Key Points: 
  • VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC).
  • Optimi boasts an extensive genetic bank of over 200 psilocybin-containing mushroom strains, making it among the largest globally.
  • Chase, Chief Science Officer at Optimi, expressed enthusiasm for the partnership and its potential impact on mushroom science and research.
  • "The Kwantlen Polytechnic University Applied Genomics Centre brings a wealth of experience and expertise in genomics research, making it an ideal partner for Optimi’s innovative initiatives in mushroom science,” he added.

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Retrieved on: 
火曜日, 4月 16, 2024
Patient, DiGeorge syndrome, American College, MYGN, Pregnancy, Test management, Myriad Genetics, Ventricular septal defect, FACMG, MD, Doctor of Philosophy, Genetic testing, Medical genetics, Genetics, DNA, SNP, PPV, Genomics, Medicine, FACOG, Dietary supplement

“This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.

Key Points: 
  • “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
  • This study enables greater confidence for providers when they receive positive screening results for 22q11.2 microdeletion.
  • 22q11.2 deletion syndrome (22q11.2DS), often called DiGeorge syndrome, is caused by deletions on chromosome 22 (22q11.2 microdeletions).
  • The American College of Medical Genetics and Genomics recently recommended that 22q11.2DS screening be offered to all pregnant patients.

ProPhase Labs Unveils Project ZenQ-AI

Retrieved on: 
火曜日, 4月 16, 2024
Project, Cancer, Genomics, Whole genome sequencing, Safety, AI, Esophageal cancer, Nebula Genomics, Genetics, Machine learning, WGS, Doctor of Philosophy, DNA, SNP, Therapy, ADC, Marker beacon, Prophase, NVIDIA, Genome, EAC, Database, Diagnosis, CIO, Biomarker, Algorithm, Spacecraft, Medical device

Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.

Key Points: 
  • Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
  • "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
  • To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
  • ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Retrieved on: 
水曜日, 5月 1, 2024
Health, Consumer, Women, Genetics, Baby, Maternity, Clinical Trials, Biotechnology, Fetus, Nucleic acid thermodynamics, Gamma globulin, Episcopal conference, American College, NTRA, Laboratory, RHD (gene), Anemia, Risk, Pregnancy, Blood, Northwell Health, Quality, Genetic testing, Obstetrics, DNA, SNP, ACOG, ASHG, NIPT, Patient, Human genetics, Society, Physician, Antibody, Panorama, Dietary supplement

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.
  • This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
  • Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants.
  • The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology.

Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only

Retrieved on: 
月曜日, 4月 15, 2024
Health, Medical Devices, Infectious Diseases, Genetics, Research, Science, Biotechnology, RUO, Chlamydia trachomatis, Neisseria gonorrhoeae, Laboratory, Trichomonas vaginalis, Collection, STI, DNA, SNP, Mycoplasma genitalium, Vaccine

Applied BioCode Inc., a pioneer in molecular diagnostics, proudly announces the launch of its latest innovation, the BioCode® STI + Resistance Panel (RUO).

Key Points: 
  • Applied BioCode Inc., a pioneer in molecular diagnostics, proudly announces the launch of its latest innovation, the BioCode® STI + Resistance Panel (RUO).
  • The panel is exclusively intended for research purposes and is not intended for diagnostic procedures.
  • Engineered with precision for seamless integration with the BioCode® MDx-3000 automated system, it delivers timely test results approximately 4 hours post-DNA extraction.
  • “We are thrilled to announce the release of the STI + Resistance Panel for research use under our new product strategy.